[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

Trial ID or NCT#

NCT02695628

Status

not recruiting iconNOT RECRUITING

Purpose

This clinical trial studies how well 18F-fluoromisonidazole ([18F]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. [18F]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by [18F]FMISO is picked up by a PET scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible

Official Title

Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Histopathologic or imaging and clinical features of tumor(s) diagnostic for hepatocellular carcinoma with at least one tumor >= 1.5 cm; imaging features diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and Data System (LIRADS) 4 or greater - Total bilirubin < 3.0 - Child Pugh A or B - Tumor amenable to transcatheter arterial embolization - Able to provide informed consent
Exclusion Criteria:
  1. - Uncontrolled large ascites - Main or segmental portal vein thrombosis - Locoregional treatment of hepatocellular carcinoma within the prior 3 months or chemotherapy within the previous 3 months - Inability or contraindication to undergo transcatheter arterial embolization - Inability to lay flat for at least 2 consecutive hours - Severe acute illness - Uncontrolled chronic illness such as hypertension, diabetes, or heart failure - Contraindication to CT or MRI contrast - Pregnancy
View All Criteria
Show Less

Investigator(s)

Rajesh Shah
Rajesh Shah
Interventional radiologist
Clinical Associate Professor, Radiology

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov